Due to its rising frequency, protracted course, strain on caregivers, and high financial burden of care, Alzheimer's disease (AD) has emerged as a significant global public health issue. The symptoms of AD have been linked to the loss of acetylcholine-containing neurons in the basal forebrain. The effectiveness of the remaining cholinergic neurons may be increased by cholinesterase inhibitors that prevent acetylcholine from being degraded. Huperzine A is a beta-amyloid protein (or peptide), glutamate, ischemia, and staurosporineinduced cytotoxicity and apoptosis-inducing agent that is a linearly competitive, reversible inhibitor of acetyl cholinesterase and is claimed to have both central and peripheral activity. Huperzine A is an active Lycopodium alkaloid that is extracted from a traditional Chinese herb. It is a potent, selective, and reversible acetylcholinesterase (AChE) inhibitor that has been used extensively in China to treat Alzheimer's disease. These qualities might make Huperzine A a promising agent for treating dementia (including AD). Huge efforts have also been made to optimise the drug delivery method in order to increase the efficacy and safety of huperzine A therapy. In this article, an effort is made to explore the huperzine A treatment for AD's current status and potential for the future.